RxDoctor Payments Data

Richard Murphy, OD

Optometrist · Montgomery, ALNPI 1780753566

Payments from drug & device makers

$1,051in general payments, 2019–2025

Across 49 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$350
  • Alcon$198
  • Kala Pharmaceuticals, Inc.$175
  • Johnson & Johnson Vision Care, Inc.$78
  • Novartis$56
  • Bausch & Lomb Americas Inc.$50
  • plus $143 from 6 others

What the payments were for

  • Food & beverage$1,051100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,051 in reported general payments places this provider in the 50th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$72,073
Medicare patients
476
Services billed
731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost120$50,615
Latanoprost934$14,483
Travoprost61$10,376
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol48$7,872
SimbrinzaBrinzolamide/Brimonidine Tart27$5,528
Timolol Maleate384$4,274
CombiganBrimonidine Tartrate/Timolol22$4,212
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat100$1,753
Fluorometholone27$1,680
Brimonidine Tartrate97$1,530
Doxycycline Hyclate42$1,418
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha63$948
Dorzolamide Hcl29$889
Prednisolone Acetate17$579
ErythromycinErythromycin Base21$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$350$54,827142 claims
AlconSimbrinza$198$5,52827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 749 optometrist providers in Alabama.

Other optometrist in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →